GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

GSK says Nucala is the only drug in the new interleukin-5 inhibitor class to be approved in Europe in a once-monthly, self-administered format, adding that studies show 96% of patients prefer self ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Teva Pharmaceutical Industries Ltd. ADR-0.95% $24.61B ...

Mepolizumab is under clinical development by GSK and currently in Phase III for Chronic Obstructive Pulmonary Disease ... company and its clinical trials play a fundamental role in drug-specific PTSR ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other undervalued defensive Stocks for 2025. The consumer defensive sector covers products that everyone ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Vaccine makers face a demand cliff as coronavirus vaccines wane, but these stocks are more than meets the eye.